Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
69°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
IO Biotech, Inc. - Common Stock
(NQ:
IOBT
)
1.580
+0.010 (+0.64%)
Streaming Delayed Price
Updated: 2:31 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about IO Biotech, Inc. - Common Stock
< Previous
1
2
Next >
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024
August 13, 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024
May 14, 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 06, 2024
Via
Benzinga
IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023
March 05, 2024
IOBT stock results show that IO Biotech missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Top 5 Health Care Stocks That May Crash This Month
January 22, 2024
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
IO Biotech: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
Expert Ratings for IO Biotech
September 28, 2023
Via
Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 27, 2023
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying
November 27, 2023
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 24, 2023
Via
Benzinga
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
September 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 15, 2023
Via
Benzinga
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 14, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 14, 2023
On Wednesday, 33 stocks hit new 52-week lows.
Via
Benzinga
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 14, 2023
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial...
Via
Benzinga
Why Are IO Biotech Shares Trading Lower Today
June 14, 2023
IO Biotech (NASDAQ: IOBT) randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 14, 2023
Via
Benzinga
Heritage Insurance And 3 Other Stocks Under $4 Insiders Are Aggressively Buying
March 21, 2023
The Dow Jones closed higher by more than 1% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 28, 2022
Via
Benzinga
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
November 21, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 05, 2022
Gainers
Via
Benzinga
Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday's Mid-Day Session
July 25, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.
Via
Benzinga
Tesla, Coinbase Global And 41 Stocks Moving In Monday's Mid-Day Session
July 18, 2022
Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering.
Via
Benzinga
IO Biotech Starts Dosing In Late-Stage IO102-IO103/Keytruda Combo Trial In Melanoma Patients
May 18, 2022
IO Biotech (NASDAQ: IOBT) dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with previously...
Via
Benzinga
IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
April 11, 2022
IO Biotech Inc (NASDAQ: IOBT)
Via
Benzinga
68 Biggest Movers From Yesterday
April 05, 2022
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.